BRIEF-Johnson & Johnson Therapy Nipocalimab Granted U.S. FDA Fast Track Designation In Systemic Lupus Erythematosus (Sle)
Johnson & Johnson +0.90% Post
Johnson & Johnson JNJ | 240.10 239.60 | +0.90% -0.21% Post |
March 3 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON THERAPY NIPOCALIMAB GRANTED U.S. FDA FAST TRACK DESIGNATION IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Source text: ID:nPn4tP9fla
Further company coverage: JNJ.N
